Answers are grounded in this paper and cite their sources.
Discovery of a selective JAK2 inhibitor in myeloproliferative neoplasms, suggesting potential for targeted therapy.
Janus kinases (JAKs) mediate cytokine and growth factor signaling by phosphorylating STAT proteins, playing a critical role in immune regulation. Among JAK family, JAK2 drives hematopoietic and immune signaling. Its dysregulation promotes myeloproliferative neoplasms (MPN) by impairing hematopoietic stem cell function. Selective JAK2 inhibition offers a promising therapeutic strategy for effective and safe MPN treatment. Starting from a non-selective JAK inhibitor, we synthesized a series of furopyrimidine derivatives to discover potent, JAK2-selective inhibitors. Structural optimization led to potent JAK2 inhibitors with improved selectivity. Further refinements led to compound 14 , which exhibited approximately 10-fold selectivity for JAK2 over JAK1 and negligible inhibition of JAK3 and TYK2 in biochemical assays. These findings provide a framework for designing novel JAK2-selective inhibitors with improved potency and specificity for MPN therapy. • A novel series of furopyrimindine derivatives has been discovered as JAK inhibitors • Compound 14 exhibited high selectivity toward JAK2 among the JAK family. • Docking study suggested that terminal heteroatoms on substituents enhance selectivity.
No takes yet. Share an insight, caveat, or question.
김민기 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: